Escend Pharmaceuticals, Inc.

Escend develops small molecule therapeutics to ablate cancer stem cells.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Menlo Park, CA, US
  • Currency USD
  • Founded February 2014
  • Employees 2
  • Incorporation Type C-corp
  • Website escendpharma.com

Company Summary

Escend leverages on previous data to develop small molecules for oncology orphan indications. Our lead, ES-3000, inhibits the development of leukemic stem cells. We are developing it for myeloid leukemia (AML). All toxicology, CMC & protocol synopsis completed. Pre-IND meeting with the FDA has been conducted and currently authoring IND for submission to initiate Phase I/II trial in refractory and relapsed AML.

Team

  • Saira Bates
    Co-founder & CEO

    Saira is a creative, dynamic and goal oriented leader with a unique combination of technical and business expertise. She has provided preclinical support to several oncology programs. Saira has seven issued and pending US patents. She has published her work in peer reviewed journals and presented at numerous scientific conferences. She has a BS in Biochemistry from Stony Brook University and a MBA from Pepperdine University.

  • Dennis Brown, Ph.D.
    Co-founder & Business Advisor

    Dennis is a serial entrepreneur and co-founded Matrix Pharmaceuticals, which was acquired by Chiron. He also founded ChemGenex Therapeutics, which merged with a publicly traded Australian company to become ChemGenex Pharmaceuticals, which was acquired Cephalon (subsequently acquired by Teva). Currently CSO of Del Mar Pharmaceuticals. Inventor on 30+ issued and pending patents.

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free